Your session is about to expire
← Back to Search
APL-2 for Age-Related Macular Degeneration
Study Summary
This trial will assess whether a treatment for age-related macular degeneration is effective and safe.
- Age-Related Macular Degeneration (AMD)
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 53 Patients • NCT04085601Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many people can sign up for this test program?
"This particular trial is not looking for new participants at this time. The date the study was first posted was August 31st, 2018 and the most recent update to the clinicaltrials.gov page was on June 20th, 2022. However, there are 329 other trials concerning geographic atrophy that are currently enrolling patients as well as 11 studies involving APL-2."
Has a trial like this ever been conducted before?
"APL-2's first clinical trial was in 2018 and sponsored by Apellis Pharmaceuticals, Inc. 21 patients were included in the study. After review, APL-2 received Phase 2 drug approval which has resulted in 11 active studies taking place across 164 cities and 26 countries."
Has the APL-2 drug been cleared by the FDA for consumer use?
"APL-2's safety is reflected by it being given a 3 on our team's 1 to 3 scale. This is due to this being a Phase 3 trial, where there exists some data affirming its efficacy along with multiple rounds of data supporting its safety."
Is this the first time that APL-2 has been trialed?
"Right now, there are 11 clinical trials studying APL-2 with 5 of them in Phase 3. Many of the research facilities for APL-2 are based in London and California; however, 593 locations worldwide are running studies for this medication."
Is this clinical trial being conducted in multiple states?
"There are a total of 77 clinical trial sites open for enrollment, these locations include Retina Consultants of Houston in The Woodlands, University of Ottawa Eye Institute in Ottawa and Retina Centre of Ottawa in Toronto."
Are we able to enroll new patients at this time?
"The clinicaltrials.gov website reveals that this study is not currently looking for patients, as the last update was on 6/20/2022. Although this particular trial is no longer active, there are 340 other studies that are still recruiting participants."
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger